147 related articles for article (PubMed ID: 38304429)
1. Nomograms confirm serum IL-6 and CRP as predictors of immune checkpoint inhibitor efficacy in unresectable hepatocellular carcinoma.
Du J; Huang Z; Zhang E
Front Immunol; 2024; 15():1329634. PubMed ID: 38304429
[TBL] [Abstract][Full Text] [Related]
2. Combination of alpha-fetoprotein and neutrophil-to-lymphocyte ratio to predict treatment response and survival outcomes of patients with unresectable hepatocellular carcinoma treated with immune checkpoint inhibitors.
Zhu HF; Feng JK; Xiang YJ; Wang K; Zhou LP; Liu ZH; Cheng YQ; Shi J; Guo WX; Cheng SQ
BMC Cancer; 2023 Jun; 23(1):547. PubMed ID: 37322411
[TBL] [Abstract][Full Text] [Related]
3. Hepatocellular carcinoma immune prognosis score predicts the clinical outcomes of hepatocellular carcinoma patients receiving immune checkpoint inhibitors.
Zhang R; Zhao H; Wang P; Guo Z; Liu C; Qu Z
BMC Cancer; 2023 Dec; 23(1):1181. PubMed ID: 38041022
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and Safety Associated With Immune Checkpoint Inhibitors in Unresectable Hepatocellular Carcinoma: A Meta-analysis.
Jácome AA; Castro ACG; Vasconcelos JPS; Silva MHCR; Lessa MAO; Moraes ED; Andrade AC; Lima FMT; Farias JPF; Gil RA; Prolla G; Garicochea B
JAMA Netw Open; 2021 Dec; 4(12):e2136128. PubMed ID: 34870682
[TBL] [Abstract][Full Text] [Related]
5. Cholesterol and C-reactive protein prognostic score predicted prognosis of immune checkpoint inhibitors based interventional therapies for intermediate-to-advanced hepatocellular carcinoma patients.
Zeng H; Zhang D; Yang Z; Hu Z; Yang Z; Fu Y; Hou J; Ngai S; Wang J; Chen J; Hu D; Zhou Z; Chen M; Zhang Y; Pan Y
Int Immunopharmacol; 2023 Feb; 115():109651. PubMed ID: 36638663
[TBL] [Abstract][Full Text] [Related]
6. Comparison of the effectiveness of chemotherapy combined with immunotherapy and chemotherapy alone in advanced biliary tract cancer and construction of the nomogram for survival prediction based on the inflammatory index and controlling nutritional status score.
Zhang Z; Wang D; Zhang J; Ruan Y; Zhao L; Yang L; Liu Z; Yang L; Lou C
Cancer Immunol Immunother; 2023 Nov; 72(11):3635-3649. PubMed ID: 37668711
[TBL] [Abstract][Full Text] [Related]
7. The combination of circulating IgM and geriatric nutritional risk index predicts the prognostic of hepatocellular carcinoma patients who underwent immune checkpoint inhibitors.
Liu C; Zhao H; Wang P; Guo Z; Qu Z
Int Immunopharmacol; 2023 Oct; 123():110704. PubMed ID: 37506504
[TBL] [Abstract][Full Text] [Related]
8. Prognostic model of immune checkpoint inhibitors combined with anti-angiogenic agents in unresectable hepatocellular carcinoma.
Li X; Sun W; Ding X; Li W; Chen J
Front Immunol; 2022; 13():1060051. PubMed ID: 36532029
[TBL] [Abstract][Full Text] [Related]
9. Increased interleukin-6/C-reactive protein levels are associated with the upregulation of the adenosine pathway and serve as potential markers of therapeutic resistance to immune checkpoint inhibitor-based therapies in non-small cell lung cancer.
Naqash AR; McCallen JD; Mi E; Iivanainen S; Marie MA; Gramenitskaya D; Clark J; Koivunen JP; Macherla S; Jonnalagadda S; Polsani S; Jiwani RA; Hafiz M; Muzaffar M; Brunetti L; Stroud CRG; Walker PR; Wang K; Chung Y; Ruppin E; Lee SH; Yang LV; Pinato DJ; Lee JS; Cortellini A
J Immunother Cancer; 2023 Oct; 11(10):. PubMed ID: 37852738
[TBL] [Abstract][Full Text] [Related]
10. Prognostic efficacy and prognostic factors of TACE plus TKI with ICIs for the treatment of unresectable hepatocellular carcinoma: A retrospective study.
Han Z; Yang F; Zhang Y; Wang J; Ni Q; Zhu H; Zhou X; Gao H; Lu J
Front Oncol; 2022; 12():1029951. PubMed ID: 36591442
[TBL] [Abstract][Full Text] [Related]
11. Identification of prognostic factors and nomogram model for patients with advanced lung cancer receiving immune checkpoint inhibitors.
Chen X; Li Z; Zhou J; Wei Q; Wang X; Jiang R
PeerJ; 2022; 10():e14566. PubMed ID: 36540802
[TBL] [Abstract][Full Text] [Related]
12. The efficacy of immune checkpoint inhibitors in advanced hepatocellular carcinoma: a meta-analysis based on 40 cohorts incorporating 3697 individuals.
Wang R; Lin N; Mao B; Wu Q
J Cancer Res Clin Oncol; 2022 May; 148(5):1195-1210. PubMed ID: 34297207
[TBL] [Abstract][Full Text] [Related]
13. C-Reactive Protein Levels Predict Responses to PD-1 Inhibitors in Hepatocellular Carcinoma Patients.
Zhang Y; Lu L; He Z; Xu Z; Xiang Z; Nie RC; Lin W; Chen W; Zhou J; Yin Y; Xie J; Zhang Y; Zheng X; Zhu T; Cai X; Li P; Chao X; Cai MY
Front Immunol; 2022; 13():808101. PubMed ID: 35185894
[TBL] [Abstract][Full Text] [Related]
14. The Significance of Transarterial Chemo(Embolization) Combined With Tyrosine Kinase Inhibitors and Immune Checkpoint Inhibitors for Unresectable Hepatocellular Carcinoma in the Era of Systemic Therapy: A Systematic Review.
Ke Q; Xin F; Fang H; Zeng Y; Wang L; Liu J
Front Immunol; 2022; 13():913464. PubMed ID: 35677059
[TBL] [Abstract][Full Text] [Related]
15. Body composition predicts prognosis of hepatocellular carcinoma patients undergoing immune checkpoint inhibitors.
Xiong B; Fu B; Wu Y; Gao F; Hou C
J Cancer Res Clin Oncol; 2023 Oct; 149(13):11607-11617. PubMed ID: 37400572
[TBL] [Abstract][Full Text] [Related]
16. Correlation between surrogate endpoints and overall survival in unresectable hepatocellular carcinoma patients treated with immune checkpoint inhibitors: a systematic review and meta-analysis.
Huang L; Kang D; Zhao C; Liu X
Sci Rep; 2024 Feb; 14(1):4327. PubMed ID: 38383730
[TBL] [Abstract][Full Text] [Related]
17. Clinical predictors of treatment efficacy and a prognostic nomogram in patients with lung adenocarcinoma receiving immune checkpoint inhibitors: a retrospective study.
Hu F; Peng J; Niu Y; Mao X; Zhao Y; Jiang L
J Thorac Dis; 2022 Oct; 14(10):4096-4112. PubMed ID: 36389292
[TBL] [Abstract][Full Text] [Related]
18. Early alpha-fetoprotein response predicts prognosis of immune checkpoint inhibitor and targeted therapy for hepatocellular carcinoma: a systematic review with meta-analysis.
Tian BW; Yan LJ; Ding ZN; Liu H; Meng GX; Xue JS; Han CL; Dong ZR; Hong JG; Chen ZQ; Wang DX; Li T
Expert Rev Gastroenterol Hepatol; 2023 Jan; 17(1):73-83. PubMed ID: 36476076
[TBL] [Abstract][Full Text] [Related]
19. Hepatic arterial infusion chemotherapy with anti-angiogenesis agents and immune checkpoint inhibitors for unresectable hepatocellular carcinoma and meta-analysis.
Cao YZ; Zheng GL; Zhang TQ; Shao HY; Pan JY; Huang ZL; Zuo MX
World J Gastroenterol; 2024 Jan; 30(4):318-331. PubMed ID: 38313229
[TBL] [Abstract][Full Text] [Related]
20. Comparison of Baseline
Wu M; Wang Y; Yang Q; Wang X; Yang X; Xing H; Sang X; Li X; Zhao H; Huo L
J Nucl Med; 2023 Oct; 64(10):1532-1539. PubMed ID: 37500263
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
